TriArm Therapeutics

Executive Summary

TriArm Therapeutics is a clinical-stage cell therapy company committed to democratizing access to curative CAR-T treatments through its innovative non-viral platform. Founded in 2019 and headquartered in New York, the company leverages a global presence to address the key barriers of conventional CAR-T therapies—manufacturing complexity and prohibitive cost. By utilizing a non-viral delivery system, TriArm aims to develop safer, more effective, and more affordable cell therapies for patients worldwide. The company's approach positions it as a potential disruptor in the cell and gene therapy space, targeting currently underserved patient populations.

Upcoming Catalysts (preview)

• Q4 2026Phase 1/2 Clinical Data Readout for Lead CAR-T Candidate45% success
• Q2 2026Strategic Partnership for Non-Viral Manufacturing Scale-Up60% success
• H2 2026Series C or D Funding Round Announcement70% success